S&P/ASX 200 Index (ASX: XJO) shares rose 0.37% last week and are up 4.2% in the calendar year to date (YTD).
Today is the final day of earnings season.
We will hear from Michael Hill International Ltd (ASX: MHJ) and Monash IVF Group Ltd (ASX: MVF) today.
Meanwhile, if you're keeping an eye on dividend opportunities, there are 37 ASX shares going ex-dividend this week.
Let's start the day with some new ratings from the experts (courtesy The Bull).
Image source: Getty Images
CSL Ltd (ASX: CSL)
CSL shares rose 2.39% to $172.32 apiece last week, and are up 0.2% in the YTD.
Damien Nguyen from Morgans has a buy rating on this ASX 200 healthcare share.
Nguyen said:
CSL is a global healthcare leader with strong competitive advantages across plasma therapies, vaccines and specialty medicines.
Demand for its products remain largely independent of economic conditions.
In our view, the latest full year result in 2026 is generating confidence that repeated earnings downgrades are behind CSL.
With defensive earnings, global market leadership and attractive long term growth prospects, we view CSL as an appealing investment opportunity.
Goodman Group (ASX: GMG)
The Goodman Group share price rose 2.38% to $27.92 last week, and is down 9% for the YTD.
Jonathan Tacadena from MPC Markets has a hold rating on this ASX 200 property share.
Tacadena said:
Goodman Group is a global industrial property and data centre developer. It delivered an operating profit of $2.675 billion in full year 2026, up 15.7 per cent on the prior corresponding period.
Data centres drove work in progress to $19.7 billion across 50 projects in 12 countries.
Property investment income of $722.1 million was up 7 per cent. Occupancy remained high at 95.6 per cent.
The company is targeting earnings per share growth of 9 per cent in full year 2027.
Earnings momentum and management quality justify holding the position.
Commonwealth Bank of Australia (ASX: CBA)
The CBA share price fell 0.47% to $157.25 last week, and is down 2% for the YTD.
Nguyen has a sell rating on this ASX 200 bank share, and said:
The CBA continues to deliver resilient earnings, strong capital levels and industry leading returns, reinforcing its position as Australia's premier banking franchise.
However, the earnings growth outlook remains relatively modest as intense competition and margin pressure possibly weigh on profitability.
Despite these headwinds, the stock trades at a significant premium to its peers and historical valuations.
With limited scope for earnings upgrades, we believe the share price leaves little room for disappointment.
